Cancer Research Technology has signed an agreement with Bayer Schering Pharma AG, Germany, to evaluate new leptin antagonist peptides as potential experimental treatments, initially in the area of gynaecological diseases, including cancer.
25 August, 2010
Cancer Research Technology has signed a deal to provide biotech company ValiRx PLC with the global rights to develop a promising compound to treat hormone-resistant prostate cancer.
16 August, 2010
Numerate and Intellikine have announced the successful conclusion of their research collaboration to discover novel small-molecule compounds targeting the PI3K/mTOR signaling pathway.
11 August, 2010